[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611548":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":47,"collaborators":20,"id":49,"slug":20,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-XACP3","EXPERIMENTAL","Each subject receives a single intravenous injection of 68Ga-XACP3 and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET\u002FCT), 68Ga-XACP3 PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET\u002FCT), 68Ga-XACP3 PET\u002FCT","Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (68Ga-PSMA) and 68Ga-XACP3, and undergoes PET\u002FCT imaging within the specified time.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Liang Zhao","CONTACT","86 18818350620","wzhaoliang01@163.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Haojun Chen, MD, PhD","86 18659285282","leochen0821@foxmail.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Xiamen","Fujian","361000","China",{"type":39,"coordinates":40},"Point",[41,42],118.08187,24.47979,{"lat":42,"lon":41},[45],{"name":23,"role":24,"phone":46,"phoneExt":20,"email":26},"86 0592-213-7366",{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100611548",false,"NCT07242014","68Ga-XACP3 PET\u002FCT in Prostate Cancer","PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);\n* Patients who had scheduled both standard-of-care imaging (68Ga-PSMA PET\u002FCT) and 68Ga-XACP3 PET\u002FCT scans;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.","MALE","18 Years","80 Years",{"count":59,"type":60},60,"ESTIMATED","INTERVENTIONAL",[63],"NA","The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET\u002FCT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET\u002FCT.",[66,67,68],"Prostate Cancer","PET\u002FCT","ACP3",[66,67,68],"2025-11-17",{"date":72,"type":73},"2025-11-21","ACTUAL",{"date":75,"type":73},"2025-09-01",{"date":77,"type":60},"2027-10-01",{"name":5,"class":6},1]